Doximity, Inc. $DOCS Shares Sold by Creative Planning

Creative Planning lowered its stake in shares of Doximity, Inc. (NASDAQ:DOCS) by 6.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,906 shares of the company’s stock after selling 2,106 shares during the quarter. Creative Planning’s holdings in Doximity were worth $1,957,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Doximity by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 12,194,492 shares of the company’s stock valued at $707,646,000 after acquiring an additional 990,923 shares during the last quarter. William Blair Investment Management LLC lifted its position in shares of Doximity by 13.8% during the second quarter. William Blair Investment Management LLC now owns 5,219,394 shares of the company’s stock worth $320,158,000 after purchasing an additional 634,927 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Doximity by 7.7% during the second quarter. Geode Capital Management LLC now owns 3,639,898 shares of the company’s stock worth $223,829,000 after purchasing an additional 261,319 shares during the last quarter. Invesco Ltd. grew its stake in Doximity by 54.8% in the first quarter. Invesco Ltd. now owns 1,969,326 shares of the company’s stock worth $114,280,000 after purchasing an additional 696,923 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Doximity by 130.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,966,801 shares of the company’s stock valued at $114,133,000 after buying an additional 1,113,076 shares during the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Doximity

In other Doximity news, Director Kira Scherer Wampler sold 2,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $66.44, for a total transaction of $132,880.00. Following the completion of the transaction, the director owned 19,839 shares in the company, valued at approximately $1,318,103.16. The trade was a 9.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $75.00, for a total value of $1,500,000.00. Following the completion of the transaction, the director directly owned 3,221 shares of the company’s stock, valued at approximately $241,575. The trade was a 86.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 32,000 shares of company stock worth $2,339,580. 31.30% of the stock is owned by company insiders.

Doximity Price Performance

Shares of NASDAQ DOCS opened at $51.09 on Wednesday. The firm has a market capitalization of $9.62 billion, a PE ratio of 51.09, a P/E/G ratio of 4.10 and a beta of 1.36. Doximity, Inc. has a 1-year low of $46.04 and a 1-year high of $85.21. The business’s fifty day moving average price is $64.50 and its two-hundred day moving average price is $62.04.

Doximity (NASDAQ:DOCS) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.07. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter in the prior year, the business earned $0.30 earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis. Doximity has set its FY 2026 guidance at EPS. Q3 2026 guidance at EPS. Equities research analysts expect that Doximity, Inc. will post 0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on DOCS. Piper Sandler increased their target price on Doximity from $65.00 to $69.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Robert W. Baird raised their price objective on Doximity from $75.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, September 11th. BMO Capital Markets started coverage on shares of Doximity in a report on Thursday, November 13th. They issued a “market perform” rating and a $55.00 price objective for the company. Zacks Research cut shares of Doximity from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Finally, Evercore ISI reduced their price target on shares of Doximity from $81.00 to $70.00 and set an “outperform” rating on the stock in a research report on Friday, November 7th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Doximity currently has an average rating of “Moderate Buy” and an average target price of $68.22.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.